Phase I clinical trial of daily oral gleevac (imatinib mesylate, formerly known as ST157) and one hour weekly paclitaxel infusion as a combined regimen for advanced or metastatic solid tumors refractory to standard therapy

Trial Profile

Phase I clinical trial of daily oral gleevac (imatinib mesylate, formerly known as ST157) and one hour weekly paclitaxel infusion as a combined regimen for advanced or metastatic solid tumors refractory to standard therapy

Not stated
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2006

At a glance

  • Drugs Imatinib (Primary) ; Paclitaxel (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top